The kidneys filter approximately 200 liters of blood every day. Kidney cancer arises when cells in the kidney grow uncontrollably — most commonly in the tubular cells of the renal cortex, producing what is called renal cell carcinoma (RCC).
Kidney cancer is one of the ten most common cancers in the United States, with approximately 81,610 new cases and about 14,390 deaths expected annually. It is roughly twice as common in men as in women, and most cases occur between ages 50 and 70.
The vast majority of kidney cancers are renal cell carcinomas — a family of cancers arising from the epithelial cells lining the kidney’s filtration tubules. RCC comprises more than 85% of all kidney malignancies and is the focus of this page. Other, less common tumors of the kidney are noted in the types section below.
New U.S. cases per year
Cases in men
Cases in women
Peak age at diagnosis
Not every mass found in the kidney is cancer. When an incidental kidney mass is discovered on imaging, understanding its size and characteristics helps guide the most appropriate next step — whether that is observation, biopsy, ablation, or surgery.
< 3 cm
T1a tumors
About 80% of small renal masses are malignant; roughly 20% are benign (oncocytomas, angiomyolipomas, complex cysts).
Metastatic risk at presentation is very low — less than 1%. Average growth rate is 3–5 mm per year. Active surveillance is a reasonable option for carefully selected patients.
3 – 4 cm
T1a / T1b boundary
Metastatic risk rises — approximately 5% of masses over 4 cm may have metastasized at presentation.
Treatment is typically recommended. Partial nephrectomy is preferred when technically feasible. Ablation is an alternative for poor surgical candidates.
4 cm
T1b and above
Higher probability of aggressive pathology and regional or distant spread. Surgical resection is generally recommended for fit patients.
Complete staging workup (chest imaging, lymph node assessment) is essential before treatment planning.
Oncocytomas, angiomyolipomas (AML), multilocular cystic nephromas, and benign complex renal cysts can all appear as solid or cystic masses on imaging. When the diagnosis is uncertain, a renal mass biopsy can provide tissue confirmation before committing to surgery.
Renal cell carcinoma is not a single disease — it is a family of distinct tumor types with different genetic drivers, behaviors, and treatment sensitivities. Subtype classification matters for prognosis and for selecting the right systemic therapy in advanced disease.
The most prevalent subtype. Often driven by loss of the VHL tumor suppressor gene. Generally responsive to VEGF-targeted therapies and immune checkpoint inhibitors. May be associated with hereditary VHL disease.
Has two subtypes: Type 1 (MET-driven, generally indolent) and Type 2 (more aggressive, associated with fumarate hydratase mutations and HLRCC syndrome). Responds differently to targeted therapies than ccRCC.
Arises from cortical collecting duct cells. Generally slow-growing with a favorable prognosis. Associated with Birt-Hogg-Dubé syndrome. Responds poorly to VEGF-targeted therapies used in ccRCC.
Rare and often aggressive subtypes. Collecting duct carcinoma typically presents at advanced stage. Renal medullary carcinoma is almost exclusively found in patients with sickle cell trait and is very aggressive.
Originates from the urothelial lining of the renal pelvis or ureter — not from the kidney parenchyma. It is biologically and clinically a distinct disease from RCC, managed like bladder cancer rather than kidney cancer. Treatment involves ureteroscopy, nephroureterectomy, or intraluminal therapy depending on stage.
The most common kidney cancer in children, typically diagnosed between ages 3 and 5. Treated with a combination of surgery, chemotherapy, and sometimes radiation. Outcomes are generally excellent — cure rates exceed 90% in early-stage disease.
Several modifiable and non-modifiable factors increase the likelihood of developing kidney cancer. Addressing modifiable risks — particularly smoking, blood pressure, and weight — can meaningfully reduce lifetime risk.
Approximately doubles kidney cancer risk. Risk is proportional to pack-years and persists for years after quitting, though it does decrease over time.
One of the strongest modifiable risk factors. Excess adipose tissue alters hormone levels (particularly estrogen) and promotes chronic inflammation, both of which drive RCC development.
Long-standing high blood pressure is an independent risk factor for RCC, separate from the medications used to treat it. Blood pressure control may reduce risk.
Patients on long-term dialysis develop acquired cystic kidney disease, which significantly increases the risk of developing RCC within the cystic kidneys.
First-degree relatives of someone with kidney cancer have roughly twice the risk. Several specific hereditary syndromes (VHL, HLRCC, BAP1, SDHB) substantially elevate risk.
Trichloroethylene (a solvent), cadmium, asbestos, and certain herbicides have been associated with increased kidney cancer risk in occupational exposure studies.
Approximately 3–5% of kidney cancers are hereditary, caused by germline mutations in specific cancer susceptibility genes. Suspicion should be raised when kidney cancer occurs at a young age, is bilateral or multifocal, or when there is a strong family history. Genetic counseling is recommended in these settings.
| Syndrome | Gene | RCC Subtype | Other Features | Management Considerations |
|---|---|---|---|---|
| Von Hippel-Lindau (VHL) | VHL | Clear cell RCC (bilateral, multifocal) | CNS/retinal hemangioblastomas, pancreatic cysts/NETs, pheochromocytoma | Surgery when largest tumor reaches 3 cm; belzutifan (HIF-2α inhibitor) FDA-approved for VHL-associated RCC |
| BAP1 Tumor Predisposition | BAP1 | Clear cell RCC; also non-RCC | Mesothelioma, uveal melanoma, skin tumors | Enhanced surveillance; surgical management similar to sporadic ccRCC |
| Hereditary Leiomyomatosis & RCC (HLRCC) | FH | Papillary type 2 (aggressive) | Cutaneous & uterine leiomyomas | Early aggressive surgery; tumors can metastasize even when small; erlotinib + bevacizumab active |
| SDH-deficient RCC | SDHB/C/D | SDH-deficient RCC | Paraganglioma, pheochromocytoma, GI stromal tumors | Surveillance from young age; surgical resection preferred; avoid mTOR inhibitors |
| Tuberous Sclerosis Complex (TSC) | TSC1/2 | Multiple subtypes; also AML | Epilepsy, cognitive disability, skin lesions, pulmonary LAM | Everolimus (mTOR inhibitor) effective for RCC and AML in TSC; AML managed with embolization or surgery |
If you were diagnosed with kidney cancer before age 46, have a family history of kidney cancer, or have bilateral or multifocal tumors, ask your urologist about referral for genetic counseling and germline testing.
Kidney cancer is often called a “silent” cancer — early-stage tumors rarely cause symptoms. The classic triad of flank pain, hematuria, and a palpable abdominal mass is actually uncommon and usually indicates advanced disease when it does occur. More than 50% of kidney cancers are now discovered incidentally on imaging.
Visible (gross) or microscopic — may be intermittent. Most common presenting symptom when one does occur.
A persistent dull ache on one side of the lower back or flank, not related to injury.
A firm lump felt in the flank or abdomen — more common with larger tumors
Loss of appetite, unintentional weight loss, or persistent tiredness may reflect advanced disease.
Intermittent fevers not explained by an identifiable infection — a paraneoplastic symptom.
Hypertension, hypercalcemia, polycythemia, or abnormal liver enzymes (Stauffer syndrome) can be caused by substances the tumor secretes.
If you have blood in your urine or a combination of the above symptoms, prompt evaluation is important. Contact us to arrange an assessment.
Diagnosis of a kidney mass involves a combination of imaging to characterize the lesion and, in selected cases, biopsy to confirm the cell type before treatment. Kidney cancer is unique in that many patients proceed directly to surgery without biopsy when the imaging characteristics are strongly suspicious.
A contrast-enhanced CT scan of the abdomen and pelvis is the standard initial study. It characterizes the mass (solid vs. cystic, enhancement pattern, fat content), assesses the renal vein and inferior vena cava for tumor thrombus, and evaluates regional lymph nodes. MRI is preferred for patients with impaired kidney function, contrast allergy, or when IVC involvement is suspected.
CT of the chest is performed to assess for pulmonary metastases, which are the most common site of RCC spread. A chest X-ray is an acceptable alternative for low-risk (small, incidentally found) masses.
Urinalysis checks for microscopic hematuria. Blood tests assess baseline kidney function (creatinine, eGFR), liver function, complete blood count, and electrolytes (calcium) — all important for staging and treatment planning, particularly if partial nephrectomy or systemic therapy is anticipated.
Not required before all kidney surgeries — imaging is often diagnostic. Biopsy is most useful when: (a) the diagnosis would change management (e.g., lymphoma or metastasis rather than primary RCC), (b) a patient is considering active surveillance and wants tissue confirmation, or (c) systemic therapy is being considered without surgery.
Performed only when symptoms (bone pain, elevated alkaline phosphatase, neurological symptoms) or high-stage disease suggest the possibility of bone or brain metastases.
Renal cysts are graded on the Bosniak scale (I through IV) based on CT/MRI characteristics. Class I and II cysts are benign; Class IIF requires follow-up imaging; Class III and IV lesions carry meaningful malignancy risk and often warrant surgical evaluation.
Kidney cancer is staged using the TNM system. Accurate staging — particularly whether the tumor is confined to the kidney or has spread beyond it — determines the treatment approach and gives the most reliable prognostic information.
Tumor ≤7 cm, confined entirely within the kidney. T1a (≤4 cm) and T1b (4–7 cm). No lymph node or distant spread. Highly curable — 5-year survival exceeds 93%. Partial nephrectomy is standard treatment when feasible.
Tumor >7 cm, still confined to the kidney. No regional lymph node or distant metastasis. Surgery is curative in most cases. Partial nephrectomy remains the goal when technically feasible; radical nephrectomy if not.
Tumor extends into the renal vein, inferior vena cava (IVC), or adrenal gland (T3), OR one regional lymph node is involved (N1), but no distant metastasis. IVC thrombus extension — even into the right atrium — can still be addressed surgically with curative intent at experienced centers.
Tumor has grown beyond Gerota's fascia into adjacent structures (T4), or distant metastases are present (M1). Most common sites: lungs, bone, liver, adrenal gland, and brain. Systemic therapy is the primary treatment, though cytoreductive nephrectomy is considered in selected patients.
The management of kidney cancer is highly individualized. Treatment decisions depend on the tumor’s size, stage, and location within the kidney; the patient’s baseline kidney function; overall health and surgical fitness; and personal preferences. Most patients with localized RCC are curable with surgery.
| Clinical Scenario | Preferred Approach | Alternatives |
|---|---|---|
| Solid mass <3 cm, older/frail patient or significant comorbidities | Active Surveillance | Ablation if growth observed |
| Solid mass <4 cm, favorable anatomy, fit patient | Partial Nephrectomy | Ablation (cryoablation or RFA) |
| Solid mass 4–7 cm (T1b), preserved contralateral kidney | Partial Nephrectomy | Radical Nephrectomy if partial not feasible |
| Solid mass >7 cm (T2) or central/hilar location | Radical Nephrectomy | Partial if nephron-sparing is critical (solitary kidney) |
| Poor surgical candidate (small mass, high comorbidity) | Percutaneous Ablation | Active surveillance; SBRT if ablation not feasible |
| Inoperable primary tumor, unable to undergo ablation or anesthesia | SBRT | Active surveillance in very frail patients |
| Metastatic RCC, good performance status | IO + TKI Combination | IO + IO combination (nivolumab + ipilimumab) |
Active surveillance (AS) involves close monitoring of a renal mass with serial imaging rather than immediate intervention. It is most appropriate for small masses (<3 cm) in older patients, those with significant comorbidities that make surgery high-risk, or patients with limited life expectancy from other conditions.
Small renal masses grow slowly — the median growth rate is just 3–5 mm per year — and the risk of developing metastatic disease while on surveillance is very low (<1–2% for masses under 3 cm). Delayed intervention does not appear to worsen oncologic outcomes compared to immediate treatment in this setting.
Cross-sectional imaging (CT or MRI) every 3–6 months in the first year, then annually. If a mass grows beyond 3–4 cm or shows rapid growth kinetics (>5 mm/year), intervention is typically recommended. Renal mass biopsy may be considered to confirm histology if the decision to intervene is uncertain.
Partial nephrectomy — removing only the tumor and a margin of surrounding normal kidney — is the gold-standard treatment for T1 tumors and is preferred whenever technically feasible for larger tumors as well. Preserving kidney tissue protects long-term kidney function, reducing the risk of chronic kidney disease (CKD), cardiovascular events, and dialysis dependency.
| Open Partial Nephrectomy | |
|---|---|
| Best for | Very complex, large, or hilar tumors requiring extended warm ischemia |
| Incision | Flank or midline; full access to kidney |
| Hospital stay | 3–5 days |
| Recovery | 4–6 weeks |
| Ischemia time | Can be performed without clamping in some cases |
| Robotic Partial Nephrectomy | |
|---|---|
| Best for | Most T1 tumors; increasingly used for complex cases |
| Incision | Several small port sites |
| Hospital stay | 1–2 days |
| Recovery | 2–3 weeks |
| Ischemia time | Warm ischemia typically <25 minutes; off-clamp increasingly common |
Tumor complexity is quantified using scoring systems (RENAL, PADUA) based on size, location relative to the sinus, proximity to collecting system, and exophytic proportion. Higher-complexity tumors may require a more experienced surgical approach but can still often be managed with partial nephrectomy.
Radical nephrectomy — complete removal of the kidney, Gerota’s fascia, and regional lymph nodes — is indicated when the tumor is too large or centrally located for nephron-sparing surgery, when the contralateral kidney is normal and functional, or when locally advanced disease (T3/T4) requires a wider resection.
The adrenal gland is preserved in most cases unless imaging or intraoperative findings suggest direct adrenal involvement. A lymph node dissection provides staging information but has not been proven to improve survival in clinically node-negative disease.
Robotic or laparoscopic radical nephrectomy is the standard of care for most patients with localized disease. Compared to open surgery, minimally invasive techniques result in less blood loss, shorter hospital stays (typically 1–2 days), and faster return to normal activity — without compromising cancer control.
When RCC extends as a tumor thrombus into the renal vein or inferior vena cava (IVC), surgical removal of both the kidney and the thrombus is potentially curative and is recommended at experienced urologic oncology centers. Level of thrombus extension (infradiaphragmatic vs. supradiaphragmatic vs. intracardiac) determines the complexity of the procedure and whether cardiothoracic surgical collaboration is required.
Ablative therapies destroy tumor tissue in place using extreme cold (cryoablation) or heat (radiofrequency ablation, microwave ablation) — without removing the kidney. They are performed percutaneously under CT or ultrasound guidance and are typically done under sedation rather than general anesthesia.
Most widely used
Probes inserted through the skin freeze the tumor to −40°C or below, creating an “ice ball” that destroys cells. Multiple freeze-thaw cycles are performed.
Preferred for posterior tumors and can be monitored in real-time on CT. Local recurrence rates of 5–10% for T1a tumors.
Heat-based
Electrical current generates heat (up to 100°C), coagulating the tumor. Performed percutaneously under CT or ultrasound guidance.
Well-established for small (<3 cm) exophytic tumors. Less effective for tumors near the collecting system or major vessels.
Ideal for
Patients with small (<4 cm), peripherally located tumors who are poor surgical candidates due to age, comorbidities, or compromised kidney function.
Also considered for patients with a solitary kidney, hereditary RCC (multiple tumors over a lifetime), or those who decline surgery.
Ablation carries higher local recurrence rates than surgery for equivalent-sized tumors (approximately 5–15% vs. <3% for surgery at 5 years). However, most recurrences can be re-treated. For small, peripheral tumors in carefully selected patients, ablation provides excellent cancer control with minimal impact on kidney function.
SBRT — also called stereotactic ablative radiotherapy (SABR) — delivers high doses of precisely focused radiation to the kidney tumor over a small number of treatment sessions (typically 3–5 fractions). It is not a first-line treatment for kidney cancer, which is historically considered radiation-resistant at conventional doses. SBRT’s higher dose-per-fraction overcomes this resistance and achieves meaningful local tumor control without surgery.
SBRT for the primary kidney tumor is reserved for patients who cannot safely undergo surgery or percutaneous ablation — for example due to severe cardiopulmonary disease, anticoagulation that cannot be safely bridged, tumor anatomy that makes ablation technically hazardous (e.g., proximity to bowel or ureter), or patient refusal of invasive procedures. It is not considered equivalent to surgery or ablation in fit patients, but offers a meaningful local control option for those with no other alternative.
Treatment is delivered on an outpatient basis using a linear accelerator with real-time image guidance (image-guided SBRT or IGRT). Each session takes 30–60 minutes; the full course is typically completed in 1–2 weeks. Side effects are generally mild — fatigue, localized discomfort — though radiation nephritis (inflammation of kidney tissue) and rare bowel or duodenal toxicity can occur depending on tumor location.
Prospective studies and registry data report local control rates of approximately 85–95% at 3 years for T1 tumors treated with SBRT. Kidney function is generally preserved better than with radical nephrectomy, and may be comparable to partial nephrectomy in some series. Long-term data beyond 5 years remain limited compared to surgery and ablation, and SBRT for RCC is not yet universally covered by all insurers — discuss coverage with your care team before planning.
SBRT for kidney cancer is planned in collaboration with a radiation oncologist experienced in abdominal SBRT. At Bansal Urology, Dr. Bansal coordinates with radiation oncology partners to evaluate patients who may be candidates.
This section covers SBRT directed at the primary kidney tumor. The role of radiation for bone, brain, or other metastatic sites is a separate clinical discussion.
Prognosis in kidney cancer is strongly linked to stage at diagnosis. The majority of patients diagnosed with localized disease can expect long-term cure with appropriate surgical treatment. For metastatic disease, outcomes have improved dramatically in the era of IO+TKI combination therapies.
| Stage | Description | 5-Year Survival (Approximate) | Comment |
|---|---|---|---|
| Stage 1 | Tumor ≤7 cm, confined to kidney | ~93% | Highly curable; partial nephrectomy standard when possible |
| Stage 2 | Tumor >7 cm, confined to kidney | ~74% | Surgery curative in most; adjuvant pembrolizumab may reduce recurrence risk in high-risk cases |
| Stage 3 | Extends to renal vein, IVC, or N1 | ~53% | Adjuvant pembrolizumab (KEYNOTE-564) reduces recurrence risk; discuss with your oncologist |
| Stage 4 | Beyond Gerota’s fascia or distant metastasis | ~13% (historic); improving with modern IO+TKI regimens | Median OS now exceeding 4 years with combination therapy; long-term remissions in a subset |
Following nephrectomy, patients with intermediate-high or high-risk localized disease (T2 high grade, T3–T4, or M1 NED) may benefit from 12 months of adjuvant pembrolizumab. Discuss eligibility with your oncologist after surgery.
Survival statistics reflect population-level data. Individual prognosis depends on tumor grade, histological subtype, performance status, and response to treatment.
Post-treatment surveillance is critical — the majority of recurrences occur within the first 3–5 years. The intensity of follow-up is stratified by the patient’s risk group at the time of surgery.
| Risk Group | Stage | Evaluation Modalities | Schedule | Duration |
|---|---|---|---|---|
| Low Risk | Stage I (T1a/T1b, N0, M0) | Physical exam; creatinine/eGFR; ultrasound or CT abdomen | Annually | Up to 5 years |
| Moderate Risk | Stage I–II (T2, N0, M0) | Physical exam; CBC, creatinine, LFTs; CT abdomen/pelvis ± chest X-ray | Every 6 months × 2 years, then annually | 5–10 years |
| High Risk | Stage II–III (T3 or N1) | Physical exam; CBC, creatinine, LFTs; CT chest/abdomen/pelvis | Every 3–6 months × 3 years, then every 6–12 months | 10 years or lifelong |
| Active Surveillance | Small mass (<4 cm), unfit or unwilling patients | Physical exam; labs; renal ultrasound, CT, or MRI | Every 3–6 months initially, then annually | Ongoing |
After partial or radical nephrectomy, kidney function should be assessed regularly — especially in patients with pre-existing CKD, hypertension, or diabetes. Nephrology co-management may be warranted.
Contrast-enhanced CT or MRI at 3–6 months post-ablation to confirm treatment success, then annually. Any residual enhancement suggests incomplete ablation requiring re-treatment.
UTUC arises from the urothelial lining of the renal pelvis or ureter — not from the kidney tissue itself. Although it is found in the kidney region, it is biologically and clinically a distinct cancer from renal cell carcinoma and is treated according to bladder cancer principles, not kidney cancer principles.
Urothelial carcinoma — the same cell type responsible for most bladder cancers — can arise anywhere along the urothelial lining from the renal pelvis to the urethra. When it originates above the bladder, in the renal pelvis or ureter, it is called upper tract urothelial carcinoma. UTUC accounts for approximately 5–10% of all urothelial cancers and roughly 5% of all kidney tumors.
UTUC shares many risk factors with bladder cancer: smoking is the most significant modifiable risk factor, followed by occupational exposures to aromatic amines (dye, rubber, leather industries), and aristolochic acid exposure (found in certain herbal medicines and endemic nephropathy regions). It is roughly twice as common in men as in women, and most patients are diagnosed in their 60s or 70s.
An important genetic risk factor is Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC) — caused by germline mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2). Lynch syndrome carriers have a lifetime UTUC risk of up to 20%, and any patient diagnosed with UTUC under age 60 should be considered for Lynch syndrome testing.
UTUC most commonly presents with painless gross or microscopic hematuria — identical to bladder cancer. Flank pain can occur when a tumor causes obstruction of urine flow. Diagnosis typically involves a CT urogram (the primary imaging modality, which visualizes the entire urothelial tract), urine cytology, and diagnostic ureteroscopy with biopsy to directly visualize and sample the lesion.
Because the entire urothelial tract shares the same lining, the bladder must also be carefully evaluated at the time of UTUC diagnosis — cystoscopy is performed routinely to rule out synchronous bladder tumors.
UTUC is staged using the TNM system, similar to bladder cancer. The muscle layer of the renal pelvis and ureter is thinner than the bladder, so tumors can invade deeply with smaller absolute tumor size. Key stages mirror bladder cancer: Ta/T1 (non-invasive or subepithelial), T2 (muscle invasion), T3 (beyond muscle into periureteric or peripelvic fat), and T4 (adjacent organ invasion or M1 metastatic).
Complete surgical removal of the kidney and the entire ipsilateral ureter, including a cuff of bladder at the ureteral orifice. Removal of the full ureter is essential — leaving a ureteral stump carries a high risk of tumor recurrence in the remnant. RNU is performed robotically or laparoscopically at Bansal Urology. A template lymph node dissection is recommended for muscle-invasive tumors. A single instillation of intravesical chemotherapy (mitomycin C) into the bladder at the time of surgery reduces the risk of subsequent bladder recurrence.
For carefully selected patients with low-grade, low-stage UTUC — particularly those with a solitary kidney, bilateral disease, or compromised renal function — endoscopic management via ureteroscopy and laser ablation of the tumor can preserve the kidney. This requires intensive surveillance with regular ureteroscopy and urine cytology and carries a higher local recurrence risk than RNU. It is not appropriate for high-grade or invasive tumors.
Cisplatin-based chemotherapy (gemcitabine + cisplatin) given before radical nephroureterectomy is recommended for patients with high-risk UTUC (high-grade, invasive on biopsy, hydronephrosis, large tumor). This is analogous to the approach in muscle-invasive bladder cancer — and is ideally administered before surgery because nephroureterectomy removes one kidney, often reducing post-operative renal function below the threshold needed for cisplatin. Patients who are cisplatin-ineligible may be considered for neoadjuvant EV + pembrolizumab in clinical trial settings.
For patients with low-grade non-invasive UTUC of the renal pelvis who are not candidates for or decline surgery, UGN-101 (pyelocalyceal mitomycin gel) is an FDA-approved endoscopic instillation therapy. A gel formulation of mitomycin C is instilled into the renal pelvis via a ureteral catheter and retained by the gel's thermosensitive properties. It offers a non-surgical option for a narrow subset of low-risk patients.
Metastatic UTUC is treated with the same systemic agents used for advanced bladder cancer. First-line therapy for cisplatin-eligible patients is gemcitabine + cisplatin, often followed by maintenance avelumab. For cisplatin-ineligible patients, pembrolizumab or enfortumab vedotin + pembrolizumab (EV+P) are active options. Second-line agents include enfortumab vedotin, sacituzumab govitecan, and erdafitinib (for FGFR-altered tumors). Molecular profiling of tumor tissue is strongly recommended given the range of actionable targets.
Patients treated for UTUC have a 30–50% lifetime risk of developing bladder cancer. Cystoscopy surveillance — typically every 3 months for the first year, then every 6 months, then annually — is mandatory after RNU or endoscopic management and should be maintained long-term. The contralateral upper tract should also be imaged periodically in patients who underwent endoscopic management.
Any patient with UTUC under age 60, with a strong family history of Lynch-associated cancers (colorectal, endometrial, ovarian), or with bilateral/multifocal UTUC should be referred for germline testing and genetic counseling.
Misclassifying UTUC as RCC — or vice versa — leads to fundamentally incorrect treatment. If you have been told you have a "kidney tumor," ask your urologist specifically whether it arises from the kidney tissue or from the collecting system.
Whether you’re seeking expert care for a urological condition or looking for a second opinion, we’re here to support you every step of the way. Reach out to schedule an appointment, ask questions, or learn more about personalized, minimally invasive treatment options tailored to your needs.
